Matinas BioPharma Holdings, Inc. (MTNB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Matinas BioPharma Holdings, Inc. (MTNB) closed at USD 2.48 on 2026-10-14, a change of +61.9 % over the past year, with a market capitalization of USD 2.37M.

Matinas BioPharma Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Matinas BioPharma Holdings, Inc. key figures

Previous close

USD 2.48 (2026-10-14)

1-year change

+61.9 %

Market cap

USD 2.37M

Enterprise value

USD 1.62M

P/E ratio (trailing)

-0.14

P/E ratio (forward)

-0.81

EPS (trailing)

-16.99

EPS (forward)

-3.00

PEG ratio

n/a

Price to book

0.57

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.62

Employees

2

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Matinas BioPharma Holdings, Inc. and compare it with other stocks.